Hormonal Therapy for Male Infertility: Who It Helps

For one group of men, yes, clearly, and it should be offered to them. For everyone else the three bodies that have looked at this do not agree, and the newest of them says these drugs belong in research rather than in clinic.

The dividing line is your own LH and FSH. If they are pathologically low -- hypogonadotropic hypogonadism -- the missing signal can be replaced and sperm production usually starts. NICE guideline NG257, published on 31 March 2026, puts that as an instruction rather than an option: "Offer gonadotrophin therapy to treat men... who have hypogonadotropic hypogonadism."

If your LH and FSH are already normal, which is the situation for most men with a poor semen result, the same guideline says these drugs belong in a clinical trial. The AUA is more permissive, and a 2026 systematic review found the controlled trials do not exist. Those three positions are set against each other further down.

So the first question is not which drug. It is which side of that line your own panel puts you on. This page carries no doses; that is a prescriber's decision made against your own repeat blood tests. To read the panel itself, start with how to read an FSH and LH result, or with what FSH, LH and testosterone actually do.

Four pictures, four different conversations.

• LH and FSH low, testosterone low. Gonadotropin treatment, and this is the one picture where nobody disagrees. NG257 1.24.1 says to offer it. The AUA calls hypogonadotropic hypogonadism an identifiable and reversible cause of male infertility, asks for the underlying reason to be established and treated first, and names hCG as the usual first drug, with FSH added when indicated. This is also the only group with a quantified outcome.
• LH and FSH normal, semen parameters impaired. Here the guidance splits. The AUA permits aromatase inhibitors, hCG or selective oestrogen receptor modulators such as clomiphene under Statement 41, but only as a Conditional Recommendation on Grade C evidence and framed as raising testosterone without suppressing sperm rather than as a fertility treatment. NG257 1.24.2 restricts gonadotrophin and anti-oestrogen therapy in exactly this group to a clinical trial.
• LH elevated. Expect less whichever guideline is used. The AUA states that men with an elevated LH, consistent with a primary testicular problem, may have a limited testosterone response to these drugs because of the testicular dysfunction itself. Worth asking about before a three-month course.
• Any man currently trying to conceive. Not androgens. NG257 1.24.3 is one sentence long: "Do not offer androgens to treat semen abnormalities." AUA Male Infertility Guideline Statement 42 is a flat prohibition on prescribing exogenous testosterone to a man interested in current or future fertility, and AUA Testosterone Deficiency Guideline Statement 23 says the same as a Strong Recommendation on Grade A evidence.

One licensing point, worth knowing before you are quoted a price: the AUA notes hCG is the only drug in this group approved for use in men, and then only for hypogonadotropic hypogonadism. Clomiphene, the aromatase inhibitors and FSH are all off-label in men. Clomiphene's licensing and trial record are in what the Clomid evidence does and does not show; testosterone's in what testosterone therapy costs fertility.

It starts sperm production in most men who have none from this cause, and it often does not get the count high enough to conceive without help. Both halves are true and the second one is usually left out.

Before the caveats, the important thing: if hypogonadotropic hypogonadism is your diagnosis, this is a treatment you should be offered, and nothing further down this page is a reason to decline it. NG257 1.24.1 is a recommendation to offer, not to consider, and the AUA asks for referral to an endocrinologist or a male reproductive specialist to get it right. The uncertainty on this page is about men who do not have this diagnosis.

Muir and colleagues pooled 41 studies and 1,673 men with pathologic gonadotropin deficiency, mean age 25, treated for a median of 18 months. Average sperm concentration reached 11.6 million per mL, 95% CI 8.4 to 14.9. Sperm were present at all in 78% of 1,673, above 1 million per mL in 55%, above 5 million in 36%, above 10 million in 24% and above 20 million in 15%. Combined hCG with FSH did better than hCG alone, and men with the congenital form did worse than men whose deficiency came from pituitary disease.

So treatment moves many men from no sperm to some sperm, which changes what is possible -- including making ICSI an option where it was not. It is a long course, a median of 18 months in that pooled data.

Then you are in the group the evidence is weakest for, and the newest guideline says so plainly. NG257 1.24.2 permits gonadotrophin or anti-oestrogen therapy for this group "only... as part of a clinical trial". That is not a warning about side effects. It is a statement that outside a trial these drugs should not be given to this group at all.

A 2026 systematic review in the Journal of Clinical Endocrinology and Metabolism looked for exactly this group, searched to February 2025, and included 9 studies and 735 men. No eligible study evaluated clomiphene. None evaluated an aromatase inhibitor. Tamoxifen showed no benefit, and neither did combined hCG with hMG.

The older evidence for anti-oestrogens here sits on a Cochrane review that Cochrane withdrew -- its PubMed record still carries the WITHDRAWN prefix -- and a great deal of confident web writing descends from it. Pooled across the five of its ten trials with secure randomisation, there was no difference in pregnancy rate: pooled odds ratio 1.26, 95% CI 0.99 to 1.56. The review notes the all-trials figure "is likely to be artificially inflated".

The AUA's own summary of this is franker than most clinic pages: clinicians should inform the male with idiopathic infertility that the use of selective oestrogen receptor modulators has limited benefits relative to the results of assisted reproduction. The detail of the clomiphene trials is on the Clomid page and is not repeated here.

Worth asking directly, because the answer decides what you are offered. All three read roughly the same literature, set a different bar for what counts as evidence, and arrived in three places. They converge only on hypogonadotropic hypogonadism and on androgens.

• The AUA permits. Aromatase inhibitors, hCG or a selective oestrogen receptor modulator under Statement 41, Conditional on Grade C; an FSH analogue under Statement 46, Conditional on Grade B.
• NICE restricts. NG257 1.24.2 confines these drugs, in men without hypogonadotropic hypogonadism, to a clinical trial. Published 31 March 2026, it is the newest of the three and the most restrictive.
• The 2026 review finds the trials absent. Konnyu and colleagues searched to February 2025 for controlled studies in exactly this group and found none evaluating clomiphene or an aromatase inhibitor.

NICE and the systematic review point the same way, and the review explains why: it opens by noting that a growing number of international guidelines recommend hormonal treatment in this group despite uncertain effects on fertility outcomes. The AUA's is one of them.

The mechanics are about study design rather than biology. The AUA's Grade B on FSH -- the strongest grade anywhere in this section -- rests mainly on a 2015 meta-analysis by Santi and colleagues, which pooled 15 controlled studies, 614 men on FSH against 661 given placebo or nothing, and found a spontaneous pregnancy odds ratio of about 4.5 (95% CI 2.17 to 9.33) pooled across 9 of them. Two things about it matter: it states explicitly that randomisation was not an inclusion criterion, and its own authors wrote that heterogeneity, a high risk of bias and the absence of criteria to guide FSH administration limit the strength of the results, concluding that use "should be cautious".

The 2026 review required controlled studies and reached a different place. FSH improved sperm count by a mean difference of 11.0, 95% CI 7.2 to 14.8, and improved concentration and motility but not morphology; only two small studies reported increases in pregnancy and neither was statistically significant. Its authors called the benefit modest and short-term with uncertain translation to pregnancy or live birth.

The Cochrane review of gonadotrophins here, updated in 2013, sits between the two: across 6 randomised trials and 456 participants it found spontaneous pregnancy higher, 16% versus 7% across 5 studies and 412 participants, but concluded the numbers were too small for final conclusions. The AUA adds a practical note of its own: FSH is not approved for use in men, and its cost-to-benefit ratio is questionable.

Commonly proposed, and here the split bites hardest. NG257 1.25.2 says simply to offer surgical sperm retrieval to manage non-obstructive azoospermia, and carves out no drug course beforehand; since these men do not have hypogonadotropic hypogonadism, 1.24.2 puts any gonadotrophin or anti-oestrogen given to them inside a trial. The AUA is more permissive but says the data are limited -- and the strongest-looking study is not randomised.

Hussein and colleagues reported a multicentre series of 612 men with non-obstructive azoospermia: 116 went to surgery untreated and formed the comparison group, and 496 received clomiphene with hCG and hMG added by hormonal response. Sperm appeared in the ejaculate in 54 of 612 men, 10.9%. Among the 442 who remained azoospermic, retrieval succeeded in 57% against 33.6% untreated. But that comparison group was not randomised — it is the men who went to surgery without treatment, not men allocated to none — which is why the AUA grades this area Conditional on Grade C.

A randomised trial of letrozole here answers a narrower question than it is usually cited for: 46 men who were azoospermic or cryptozoospermic and selected for a testosterone-to-oestradiol ratio below 10, of whom only 11 were actually azoospermic. Sperm concentration, motility and the three hormones rose on letrozole and not on placebo, 8 of the 22 treated men had side effects against none on placebo, and the published abstract does not report pregnancy at all. What retrieval involves is set out in what TESE is and when it is used and whether azoospermia is obstructive.

Time is the cost most men underestimate. A semen analysis cannot report on a change made less than about three months earlier: newly made sperm first appeared in the ejaculate at a mean of 64 days give or take 8 in the men Misell labelled directly, and NG257 1.17.4 asks for repeat confirmatory tests "ideally 3 months after the initial analysis to allow time for the cycle of spermatozoa formation to be completed". So the minimum honest trial is one quarter, and in proven gonadotropin deficiency the pooled median course was 18 months.

On money, the only Indian figures retrieved here are for infertility care broadly, not for these drugs. An ICMR study interviewed couples at five tertiary facilities between April 2022 and March 2023: median annual out-of-pocket spend Rs 11,317 overall, Rs 13,211 where the diagnosis was male infertility or uterine factor, and 59.4% of that cohort met the definition of catastrophic health expenditure -- infertility spending above 40% of annual household non-food spending.

Two questions are worth asking before starting. What outcome will we measure, and when? And what happens if the semen analysis at three months is unchanged -- because that answer decides whether this is a step in a plan or a delay in one. The delay is not only yours: the AUA states that the age of the female partner is the single most important factor in predicting a couple's chance of conception, so a long unproven course is spent from her clock too. Her equivalent test is covered in what a day-3 hormone panel shows.

Do not stop a prescribed drug on your own. Stopping some of these abruptly leaves you with neither your own hormone production nor the substitute, and the prescriber should manage the change. Book the appointment, and take both the hormone report and the semen analysis.

There is one exception to how neutral that advice sounds. If what you were started on is testosterone, or any other androgen, and you are trying to conceive, that is a conversation to have soon rather than at the next routine review. Neither guideline hedges on this one. NG257 1.24.3: "Do not offer androgens to treat semen abnormalities." AUA Statement 42: clinicians should not prescribe exogenous testosterone therapy to a man interested in current or future fertility. The reason, and what recovery looks like, is in testosterone therapy and fertility and what a low testosterone result means.

Being offered a drug with this much uncertainty attached, for something this important, is a difficult position to be put in, and it is not a sign of carelessness: the trials that would settle these questions have mostly not been run.

Sometimes the answer is neither. The AUA guideline states that the cause of an abnormal semen analysis cannot be identified in roughly three men in ten, and that it may advise a couple with a persistently low total motile count that assisted reproduction should be considered. Testing, timing, or going directly to the treatment that has been shown to produce pregnancies can all be the right answer. What causes a low sperm count sets out the alternatives.

• That clomiphene or an aromatase inhibitor improves any reproductive outcome where LH and FSH are normal. The 2026 review searched to February 2025 and found no eligible study of either.
• That anti-oestrogens raise the pregnancy rate in idiopathic poor semen quality. Pooled across the securely randomised trials of the withdrawn Cochrane review the odds ratio was 1.26, 95% CI 0.99 to 1.56, and the review states the all-trials figure is likely to be artificially inflated.
• That FSH analogue treatment improves live birth in idiopathic male infertility. The AUA's Grade B rests on a meta-analysis that did not require randomisation; the 2026 review found the pregnancy signal non-significant in the only two small studies reporting it.
• That a pre-retrieval course improves retrieval odds. The largest series used an untreated surgical comparison group rather than randomised allocation; the letrozole trial often cited alongside it reports semen and hormone changes in 46 selected men, of whom 11 were azoospermic, and does not report pregnancy at all.
• That any of these drugs raises the concentration of testosterone inside the testis, which is what sperm production depends on. That concentration is not routinely measurable. Coviello measured serum testosterone at 1.2% of the intratesticular level in 29 randomised men, and the authors stated the quantitative relationship between the testicular concentration and sperm production is not known.
• That exogenous testosterone belongs in this category at all. It suppresses the signals the other drugs are given to raise; both AUA guidelines say it should not be prescribed to a man trying to conceive, and NG257 1.24.3 says androgens should not be offered to treat semen abnormalities at all.
• That a supplement, an antioxidant or a drug improves sperm DNA integrity. NG257 1.24.6 is explicit: "Do not offer supplements, antioxidants or medical treatments to improve sperm DNA integrity (fragmentation)." [2026] The same guideline's 1.17.6 says not to carry out the test either.